Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Mol Hum Reprod ; 29(7)2023 Jun 30.
Artigo em Inglês | MEDLINE | ID: mdl-37261882

RESUMO

Human meiosis in oocytes entails an intricate regulation of the transcriptome to support late oocyte growth and early embryo development, both crucial to reproductive success. Currently, little is known about the co- and post-transcriptional mRNA processing mechanisms regulating the last meiotic phases, which contribute to transcriptome complexity and influence translation rates. We analyzed gene expression changes, splicing and pre-mRNA processing in an RNA sequencing set of 40 human oocytes at different meiotic maturation stages, matured both in vivo and in vitro. We found abundant untranslated region (UTR) processing, mostly at the 3' end, of meiosis-related genes between the germinal vesicle (GV) and metaphase II (MII) stages, supported by the differential expression of spliceosome and pre-mRNA processing related genes. Importantly, we found very few differences among GV oocytes across several durations of IVM, as long as they did not reach MII, suggesting an association of RNA processing and successful meiosis transit. Changes in protein isoforms are minor, although specific and consistent for genes involved in chromosome organization and spindle assembly. In conclusion, we reveal a dynamic transcript remodeling during human female meiosis, and show how pre-mRNA processing, specifically 3'UTR shortening, drives a selective translational regulation of transcripts necessary to reach final meiotic maturation.


Assuntos
Técnicas de Maturação in Vitro de Oócitos , Precursores de RNA , Humanos , Feminino , Precursores de RNA/genética , Precursores de RNA/metabolismo , Oócitos/metabolismo , Meiose/genética , Oogênese/genética
2.
Hum Mol Genet ; 22(4): 633-45, 2013 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-23118351

RESUMO

Gaucher's disease (GD) is caused by mutations in the GBA1 gene, which encodes acid-ß-glucosidase, an enzyme involved in the degradation of complex sphingolipids. While the non-neuronopathic aspects of the disease can be treated with enzyme replacement therapy (ERT), the early-onset neuronopathic form currently lacks therapeutic options and is lethal. We have developed an induced pluripotent stem cell (iPSc) model of neuronopathic GD. Dermal fibroblasts of a patient with a P.[LEU444PRO];[GLY202ARG] genotype were transfected with a loxP-flanked polycistronic reprogramming cassette consisting of Oct4, Sox2, Klf4 and c-Myc and iPSc lines derived. A non-integrative lentiviral vector expressing Cre recombinase was used to eliminate the reprogramming cassette from the reprogrammed cells. Our GD iPSc express pluripotent markers, differentiate into the three germ layers, form teratomas, have a normal karyotype and show the same mutations and low acid-ß-glucosidase activity as the original fibroblasts they were derived from. We have differentiated them efficiently into neurons and also into macrophages without observing deleterious effects of the mutations on the differentiation process. Using our system as a platform to test chemical compounds capable of increasing acid-ß-glucosidase activity, we confirm that two nojirimycin analogues can rescue protein levels and enzyme activity in the cells affected by the disease.


Assuntos
1-Desoxinojirimicina/análogos & derivados , Adamantano/análogos & derivados , Doença de Gaucher/tratamento farmacológico , Células-Tronco Pluripotentes Induzidas/efeitos dos fármacos , 1-Desoxinojirimicina/farmacologia , Adamantano/farmacologia , Antígenos de Diferenciação/metabolismo , Sequência de Bases , Diferenciação Celular , Células Cultivadas , Análise Mutacional de DNA , Neurônios Dopaminérgicos/enzimologia , Avaliação Pré-Clínica de Medicamentos , Estabilidade Enzimática/efeitos dos fármacos , Doença de Gaucher/patologia , Expressão Gênica , Glucosilceramidase/genética , Glucosilceramidase/metabolismo , Humanos , Células-Tronco Pluripotentes Induzidas/enzimologia , Células-Tronco Pluripotentes Induzidas/fisiologia , Fator 4 Semelhante a Kruppel , Lisossomos/enzimologia , Macrófagos/metabolismo , Análise de Sequência com Séries de Oligonucleotídeos , Transporte Proteico , Bibliotecas de Moléculas Pequenas , Transcriptoma
3.
Proc Natl Acad Sci U S A ; 106(22): 8918-22, 2009 Jun 02.
Artigo em Inglês | MEDLINE | ID: mdl-19458047

RESUMO

Induced pluripotent stem (iPS) cells have generated keen interest due to their potential use in regenerative medicine. They have been obtained from various cell types of both mice and humans by exogenous delivery of different combinations of Oct4, Sox2, Klf4, c-Myc, Nanog, and Lin28. The delivery of these transcription factors has mostly entailed the use of integrating viral vectors (retroviruses or lentiviruses), carrying the risk of both insertional mutagenesis and oncogenesis due to misexpression of these exogenous factors. Therefore, obtaining iPS cells that do not carry integrated transgene sequences is an important prerequisite for their eventual therapeutic use. Here we report the generation of iPS cell lines from mouse embryonic fibroblasts with no evidence of integration of the reprogramming vector in their genome, achieved by nucleofection of a polycistronic construct coexpressing Oct4, Sox2, Klf4, and c-Myc.


Assuntos
Diferenciação Celular , Células-Tronco Embrionárias/metabolismo , Vetores Genéticos/genética , Células-Tronco Pluripotentes/citologia , Regeneração , Fatores de Transcrição/genética , Animais , Técnicas de Cultura de Células , Linhagem Celular , Humanos , Fator 4 Semelhante a Kruppel , Camundongos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA